Key result
The ACAChE score demonstrated better discrimination for predicting poor anticoagulant control (TTR < 65%) than the SAMe-TT2R2 score (C-statistic 0.62 vs 0.54) in Thai patients with NVAF.
Why the study?
The SAMe-TT2R2 score has not been well validated in Asian populations and may overestimate poor anticoagulant control by treating Asian ethnicity as a risk factor.
Does the ACAChE score better predict poor anticoagulant control (TTR < 65%) compared to the SAMe-TT2R2 score in Thai patients with NVAF on warfarin?
Observational (n=864)
No
Does the ACAChE score better predict poor anticoagulant control (TTR < 65%) compared to the SAMe-TT2R2 score in Thai patients with NVAF on warfarin?
Effect estimate: C-statistic 0.62 (95% CI 0.57-0.65)
Absolute Event Rate: 0.62% vs 0.54%
The ACAChE score provides better prediction of poor warfarin control (TTR < 65%) than the SAMe-TT2R2 score in Thai patients with NVAF, potentially guiding the selection of oral anticoagulants in Asian populations.
May support ACAChE for TTR risk stratification in Thai NVAF; leaves open prospective validation before clinical use.
Background In many low- to middle-income countries in Asia, patients with NVAF usually received warfarin for thromboembolic prevention due to cost-effectiveness. The SAMe-TT2R2 score has been proposed to predict TTR in NVAF patients. However, the SAMe-TT2R2 score has not been much validated in Asian population. Interestingly, it may overestimate patients who had TTR < 65% due to regarding being Asians as a risk factor. Objectives To determine the factors predicting poor anticoagulant control on warfarin, create new scoring system, and compare with the SAMe-TT2R2 score in a Thai population with NVAF. Methods This is a retrospective study in a tertiary care hospital. We enrolled NVAF patients who received warfarin from January 2014 to December 2018. TTR was calculated based on Rosendaal method. Multiple logistic regression and AUC-ROC curve were used for analysis. Results A total of 864 patients were enrolled with mean age of 73.6 ± 11.58 years. The mean TTR was 48.1 ± 25.2%. Using multivariate regression analysis, the predictive factors for TTR < 65% were antiplatelet use (OR 4.49, p ≤ 0.001), LVEF < 40% (OR 1.92, p = 0.037), chronic kidney disease (GFR < 50 ml/min/1.73 m 2 ) (OR 1.68, p = 0.013), history of CHF (OR 1.7, p = 0.047), and age ≥ 75 years (OR 1.4, p = 0.037). Based on the regression coefficients, we developed the new scoring system called ACAChE score [A, antiplatelet use (4 points); C, chronic kidney disease, GFR < 50 ml/min/1.73 m 2 (2 points); A, age ≥ 75 years (1 point); Ch, history of CHF (2 points); E, LVEF < 40% (2 points)]. ROC curve showed discrimination performance of the ACAChE score and SAMe-TT2R2 score for prediction of TTR < 65% with the C-statistic of 0.62 (95%CI 0.57–0.65) and 0.54 (95%CI 0.50–0.58), respectively. Conclusion In Thai NVAF patients, the ACAChE score (antiplatelet use, chronic kidney disease (GFR < 50 ml/min/1.73 m 2 ), age ≥ 75 years, history of congestive heart failure, and LVEF < 40%) has better prediction for TTR < 65% than SAMe-TT2R2 score. Thus, it expected to guide the selection of oral anticoagulation in Asian patients with NVAF.
No takes yet. Share an insight, caveat, or question.
Lertsanguansinchai et al. (2021) conducted an observational in non-valvular atrial fibrillation (NVAF) (n=864). ACAChE score vs. SAMe-TT2R2 score was evaluated on Prediction of TTR < 65% (C-statistic 0.62, 95% CI 0.57-0.65). The ACAChE score demonstrated better discrimination for predicting poor anticoagulant control (TTR < 65%) than the SAMe-TT2R2 score (C-statistic 0.62 vs 0.54) in Thai patients with NVAF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: